Clinical diagnosis and treatment analysis of primary pancreatic signet-ring cell carcinoma
10.3760/cma.j.cn113884-20250112-00015
- VernacularTitle:原发性胰腺印戒细胞癌的临床诊治分析
- Author:
Hongliang LIU
1
;
Kun ZHANG
;
Bin ZHOU
;
Chuandong SUN
;
Lantian TIAN
;
Bingsong YAN
Author Information
1. 青岛大学附属妇女儿童医院肝胆胰外科，青岛 266000
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Signet-ring cell carcinoma;
Surgery;
Adjuvant therapy;
Prognosis
- From:
Chinese Journal of Hepatobiliary Surgery
2025;31(8):608-611
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the diagnosis, treatment, and prognosis of primary pancreatic signet-ring cell carcinoma (SRCC).Methods:A retrospective analysis was conducted on clinical data of 11 patients with pathologically confirmed SRCC treated at the Women and Children's Hospital Affiliated to Qingdao University and the Affiliated Hospital of Qingdao University between 2002 and 2024. The cohort included 10 male and 1 female patients, aged (65.6±9.2) years. Data on gender, age, clinical manifestations, biochemical markers, tumor biomarkers, surgical approaches, postoperative pathology, adjuvant the-rapy, and treatment outcomes were recorded. Postoperative survival was assessed via outpatient records and telephone follow-ups.Results:Among the 11 patients, all 10 male patients had a long-term smoking his-tory. Initial symptoms included epigastric pain (5 cases), jaundice (2 cases), postprandial upper abdominal discomfort (3 cases), and persistent hyperglycemia (1 case). Elevated total bilirubin with increased alanine transaminase and aspartate transaminase was observed in 4 cases, while 7 cases had normal liver function. Tumor biomarker profiles showed elevated carcinoembryonic antigen (CEA) alone in 2 cases, elevated carbohydrate antigen 19-9(CA 19-9) alone in 6 cases, concurrent elevation of CEA and CA19-9 in 2 cases, and normal tumor markers in 1 case. Tumor locations included the pancreatic head (8 cases) and pancreatic body/tail (3 cases). All patients underwent radical resection without major perioperative complications. Immunohistochemistry revealed perineural invasion (+ ) in 10 cases and Ki-67 ≥ 50% in 9 cases. Six patients received postoperative adjuvant therapy. The median disease-free survival was 14 months, and the median overall survival was 18 months.Conclusion:SRCC lacks specific clinical manifestations and carries a poor prognosis. Radical surgical resection remains the cornerstone of treatment, while adjuvant therapy may improve survival outcomes.
